Table 1 Patient characteristics according to Impella use.

From: Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices

 

All n = 60

LV Impella n = 40

RV Impella n = 20

p-value

Age, years

63 (54–70)

68.75 (62.0–75.7)

67.0 (56.25–76.75)

0.20

Impella duration, days

3.3 (1.15–7.85)

5.0 (1.15–9.4)

2.55 (1.12–7.22)

0.47

ECMO, n (%)

22 (36.7)

17 (42.5)

5 (22.5)

0.25

Major bleeding, n (%)

32 (53.3)

23 (57.5)

9 (45.0)

0.41

Access site bleeding, n (%)

1 (1,7%)

1 (2,5)

0 (0)

1.00

avWS, n (%)

31 (75.6)

21 (87.5)

10 (58.8)

0.035

Platelets, × 109/L

117 (88–196)

130.0 (89.0–242.0)

110.0 (88.0–117.75)

0.33

Hb, g/dL

9.6 (8.7–10.9)

10.0 (9.0–11.8)

9.15 (8.52–9.6)

0.016

Fibrinogen, mg/dL

302.0 (224.25–394.5)

332.5 (242.25–505.0)

299.0 (187.5–340.75)

0.33

Factor II, %

63.0 (50.0–75.75)

62.5 (51.0–75.5)

65.0 (39.75–81.25)

0.99

Factor V, %

59.0 (45.5–75.5)

59.0 (48.0–75.5)

58.5 (32.75–81.75)

0.82

Factor VII, %

53.0 (34.0–71.0)

53.0 (35.0–61.0)

56.0 (31.5–83.0)

0.60

Factor VIII, %

356.9 (281.7–450.0)

356.55 (282.52–450.0)

450.0 (238.8–450.0)

0.62

Factor X, %

57.0 (47.5–79.0)

57.0 (49.0–72.5)

67.0 (35.5–95.0)

0.72

Factor XIII, %

78.0 (65.0–94.0)

83.0 (66.0–98.0)

76.5 (63.0–87.75)

0.37

AT III, %

63.0 (54.0–74.0)

63.5 (54.25–74.5)

62.0 (44.0–74.0)

0.42

γGT, U/L

45.5 (29.25–89.25)

70.5 (34.5–128.5)

39.5 (34.25–57.5)

0.051

ALAT, U/L

59.0 (26.0–166.0)

62.0 (27.25–166.0)

56.5 (25.0–171.0)

0.65

ASAT, U/L

131.5 (40.75–458.0)

142.0 (33.25522.5)

131.5 (54.25–352.0)

0.83

TCT s

10.3 (9.2–12.57)

10.8 (9.42–12.17)

9.9 (8.65–14.97)

0.36

aPTT

35.0 (26.0–45.0)

35.4 (26.0–44.0)

34.5 (26.5–48.75)

0.83

LDH U/l

616.0 (355.0–1472.0)

537.0 (324.5–1263.0)

1282.0 (433.75–3209.5)

0.081

RC n

8.5 (0–22.25)

12.0 (0–23)

5 (0–12)

0.24

PC n

3 (1–6)

2.5 (1–6.25)

5 (2–6)

0.43

FFP n

1 (1–2)

5 (0–14.5)

6 (0–15.0)

0.82

  1. Data are shown as number (%) or median (interquartile range).
  2. ECMO extra corporal membrane oxygenation, avWS acquired von Willebrand syndrome, Hb hemoglobin, ATIII antithrombin III, γGT γ-glutamyl transferase, ALAT alanine aminotransferase, ASAT aspartate aminotransferase, TCT thrombin clotting time, aPTT activated partial thromboplastin time, LDH lactate dehydrogenase, RC red cell concentrate, PC platelet concentrate, FFP fresh frozen plasma.
Back to article page